Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
NRx Pharmaceuticals, Inc. (NRXP) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NRx Pharmaceuticals, Inc. (NRXP) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for December 30th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:
CoreCard Corporation (CCRD - Free Report) : This technology solutions and processing services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.
CoreCard Corporation Price and Consensus
CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote
CoreCard’s shares gained 44.9% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
CoreCard Corporation Price
CoreCard Corporation price | CoreCard Corporation Quote
Entrada Therapeutics, Inc. (TRDA - Free Report) : This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.
Entrada Therapeutics, Inc. Price and Consensus
Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote
Entrada’s shares gained 8.8% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
Entrada Therapeutics, Inc. Price
Entrada Therapeutics, Inc. price | Entrada Therapeutics, Inc. Quote
NRx Pharmaceuticals, Inc. (NRXP - Free Report) : This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. Price and Consensus
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
NRx’s shares gained 11.8% over the past month compared with the S&P 500’s decline of 0.7%. The company possesses a Momentum Score of A.
NRx Pharmaceuticals, Inc. Price
NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.